 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- AMY109 / Roche, Tecentriq (atezolizumab) / Roche
Phase I study of IL-8 inhibitor AMY109 plus atezolizumab (atezo) in patients (pts) with advanced solid tumours () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2573;
With no DLTs, AMY109 plus atezo was well tolerated in pts with advanced solid tumours, with no new safety signals. The partial responses were durable.
- | AMY109 / Roche
Journal: A long-acting anti-IL-8 antibody improves inflammation and fibrosis in endometriosis. (Pubmed Central) - Feb 27, 2023
In addition, experiments using cells derived from human endometriosis revealed that AMY109 inhibited the recruitment of neutrophils to endometriotic lesions and the production of monocyte chemoattractant protein-1 from neutrophils. Thus, AMY109 may represent a disease-modifying therapy for patients with endometriosis.